Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275830 | 0.84 | MAPT (0.55) | ARMAPTSMN1; SMN2GAAHTT | |
| SCHEMBL279373 | 0.83 | AR (0.40) | ARMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15221816 | 0.80 | AR (0.38) | ARMAPTLMNAALDH1A1KMT2A | |
| SCHEMBL279476 | 0.72 | MAPK1 (0.43) | ARMAPK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL279384 | 0.67 | KMT2A (0.41) | ARMAPK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL26687977 | 0.65 | VCAM1 (0.57) | MAPK1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL279598 | 0.65 | TSHR (0.44) | ARMAPK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL6438984 | 0.64 | MAPK1 (0.53) | ARMAPK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL28346773 | 0.63 | ALDH1A1 (0.40) | ARMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6703081 | 0.63 | MAPK1 (0.88) | MAPK1MAPTLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | AR 4178/4885MAPK1 2482/4885MAPT 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.